LLY

1,003.74

-0.27%↓

JNJ

228.16

-0.98%↓

ABBV

210.05

-0.51%↓

UNH

392.67

-1.85%↓

AZN

181.16

-2.29%↓

LLY

1,003.74

-0.27%↓

JNJ

228.16

-0.98%↓

ABBV

210.05

-0.51%↓

UNH

392.67

-1.85%↓

AZN

181.16

-2.29%↓

LLY

1,003.74

-0.27%↓

JNJ

228.16

-0.98%↓

ABBV

210.05

-0.51%↓

UNH

392.67

-1.85%↓

AZN

181.16

-2.29%↓

LLY

1,003.74

-0.27%↓

JNJ

228.16

-0.98%↓

ABBV

210.05

-0.51%↓

UNH

392.67

-1.85%↓

AZN

181.16

-2.29%↓

LLY

1,003.74

-0.27%↓

JNJ

228.16

-0.98%↓

ABBV

210.05

-0.51%↓

UNH

392.67

-1.85%↓

AZN

181.16

-2.29%↓

Home・Aktien・Alnylam Pharmaceuticals Inc

Alnylam Pharmaceuticals Inc

Open

BrancheGesundheitswesen

289.92 -1.08

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

286.12

Max

295.51

Schlüsselkennzahlen
By Trading Economics
Einkommen	20M 206M
Verkäufe	70M 1.2B
KGV Branchendurchschnitt	71.389 51.415
EPS	1.99
Gewinnspanne	17.649
Angestellte	2,500
EBITDA	7.1M 152M

Empfehlungen
By TipRanks
Empfehlungen	Starkes Kaufsignal
12-Monats-Prognose	+55.32% upside

Dividenden
By Dow Jones
Nächstes Ergebnis	30. Juli 2026

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	-3.1B 38B
Vorheriger Eröffnungskurs	291
Vorheriger Schlusskurs	289.92

Nachrichtenstimmung

By Acuity

50%

171 / 346 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Bullish Evidence

256.565 / 269.81 Unterstützung & Widerstand

Alnylam Pharmaceuticals Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Peer-Vergleich

Kursveränderung

Alnylam Pharmaceuticals Inc Prognose

Kursziel

By TipRanks

55.32% Vorteil

12-Monats-Prognose

Durchschnitt 452.73 USD 55.32%

Hoch 550 USD

Tief 330 USD

Basierend auf 18 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Alnylam Pharmaceuticals Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

18 ratings

Buy

Halten

Sell

Basierend auf 18 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Alnylam Pharmaceuticals Inc – Dist abgegeben haben.

Technischer Score

By Trading Central

256.565 / 269.81Unterstützung & Widerstand

Bullish events outweigh bearish events.

Recent bullish events outweigh bearish events.

Stimmung

By Acuity

171 / 346 Ranking in Gesundheitswesen

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Alnylam Pharmaceuticals Inc

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.